TabletsClinical Overview
Pramipexole is a non-ergoline dopamine agonist with high relative intrinsic activity and selectivity for dopamine D2, D3, and D4 receptor subtypes, with preferential affinity for D3 receptors in the mesolimbic system. It stimulates striatal dopamine receptors directly, bypassing degenerating nigrostriatal neurons. Indicated for the treatment of signs and symptoms of idiopathic Parkinson's disease (as monotherapy in early disease or adjunct to levodopa) and moderate-to-severe primary Restless Legs Syndrome (RLS).
Active Pharmaceutical Ingredients
Verified Clinical References
Usage Guidelines
Take orally with water, with or without food; taking with food reduces nausea. Titrate dose gradually at weekly intervals as prescribed. Do not discontinue suddenly.
General Administration Advice: Adhere strictly to the prescribed dosage, frequency, and treatment course. For oral medications, swallow with sufficient water. Never stop antibiotics, psychiatric medications, or antihypertensives abruptly without clinical direction.
Possible Side Effects
Common: Nausea, dizziness, somnolence, insomnia, constipation, asthenia, peripheral edema, orthostatic hypotension. Rare/Severe: Sudden onset of sleep during daily activities (including driving), impulse control disorders (compulsive gambling, binge eating, hypersexuality), hallucinations, and postural deformities (camptocormia).
*Note: Individual physiological responses vary. While many patients experience few or no side effects, notify your treating physician if adverse reactions persist or if hypersensitivity (angioedema, skin rash, dyspnea) occurs.
Precautions & Warnings
Warn patients about the risk of falling asleep without warning during activities requiring alertness (driving). Monitor for impulse control disorders; dosage reduction or discontinuation is curative. Dose adjustment required in renal impairment.
Schedule H (Prescription Required)
This medication is scheduled under statutory drug regulatory frameworks (CDSCO / Drugs & Cosmetics Rules). Dispensing requires a valid medical prescription from a registered medical practitioner. Self-medication or unsupervised dosage adjustment carries significant clinical risks.
Medical Disclaimer: Statutory Clinical Disclaimer: The information provided is for educational and price-transparency purposes only and does not constitute medical advice, clinical diagnosis, or treatment recommendations. Always consult a registered medical practitioner or qualified pharmacist before initiating, modifying, or substituting any medication regimen.
Pramipexole Dihydrochloride Tablets 0.25mg
Pramipexole is a non-ergoline dopamine agonist with high relative intrinsic activity and selectivity for dopamine D2, D3, and D4 receptor subtypes, with preferential affinity for D3 receptors in the mesolimbic system. It stimulates striatal dopamine receptors directly, bypassing degenerating nigrostriatal neurons. Indicated for the treatment of signs and symptoms of idiopathic Parkinson's disease (as monotherapy in early disease or adjunct to levodopa) and moderate-to-severe primary Restless Legs Syndrome (RLS).
Pramipexole 1.5mg Tablets
Pramipexole is a non-ergoline dopamine agonist with high relative intrinsic activity and selectivity for dopamine D2, D3, and D4 receptor subtypes, with preferential affinity for D3 receptors in the mesolimbic system. It stimulates striatal dopamine receptors directly, bypassing degenerating nigrostriatal neurons. Indicated for the treatment of signs and symptoms of idiopathic Parkinson's disease (as monotherapy in early disease or adjunct to levodopa) and moderate-to-severe primary Restless Legs Syndrome (RLS).